Archives
-
Allosteric XPO1 Degradation by SINE Compounds
2026-09-22
This study shows that SINE compounds do more than block XPO1-mediated nuclear export: they expose a cryptic surface that recruits the ASB8-containing CRL ubiquitin ligase and drives XPO1 degradation. Cryo-electron microscopy, cellular turnover experiments, and mechanistic analyses establish an allosteric degradation pathway that differs from conventional molecular glue and PROTAC models.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-22
A practical workflow for using Cap1-structured, pseudouridine-modified PTEN mRNA to study tumor-suppressor restoration and PI3K/Akt signaling in mammalian models. It connects careful RNA handling with nanoparticle delivery, pathway readouts, and troubleshooting for cancer research.
-
Tetrandrine: From Calcium Signals to Translation
2026-09-21
Tetrandrine is more than a natural-product calcium channel probe: it is a translational tool for connecting ion flux, inflammation, cell survival, and disease-relevant phenotypes. This article outlines how to validate its mechanism, interpret structure-based screening responsibly, and design experiments that move beyond descriptive pharmacology.
-
Cy5 NHS ester(Et): Practical Labeling Guide
2026-09-21
Cy5 NHS ester(Et) is an amine-reactive fluorescent reagent for covalently tagging proteins, peptides, and other biomolecules when a Cy5 NHS ester label is needed. It supports aqueous or DMSO-based preparation, but it should not be used in ethanol-based protocols, and prepared solutions should be used promptly rather than stored long term.
-
Maternal IL-17A and Neonatal GBS Risk
2026-09-20
A prospective mother–newborn study in Morocco links reduced IL-1β, IL-4, and IL-17A responses in GBS-colonized mothers with invasive neonatal disease. Its main translational contribution is the identification of circulating maternal IL-17A as a candidate biomarker for risk assessment, supported by cytokine profiling and ex vivo TLR stimulation.
-
GW 6471: Practical PPARα Antagonist Workflows
2026-09-19
GW 6471 enables controlled interrogation of PPARα-driven lipid remodeling, liver injury, and transcriptional responses. This guide translates zebrafish toxicology findings into practical cell, lipidomics, and PPARα-related disease-modeling workflows with concentration planning, controls, and troubleshooting guidance.
-
Vernakalant Rapidly Converts Atrial Fibrillation
2026-09-18
This phase 3 randomized trial found that intravenous vernakalant converted recent-onset atrial fibrillation to sinus rhythm substantially faster and more often than placebo. Its atrium-focused electrophysiological profile and controlled infusion protocol provide clinically relevant evidence for rapid pharmacological cardioversion, while the safety findings define important limits for interpretation.
-
Aprotinin in Protease-Controlled GRO-seq Workflows
2026-09-18
Aprotinin, or bovine pancreatic trypsin inhibitor, can be evaluated as a pre-analytical protease-control variable in complex molecular workflows. This article connects its biochemical profile with the cost-efficient GRO-seq strategy reported for bread wheat while clearly separating validated findings from exploratory assay design.
-
Selective IRAP Inhibitors from Bestatin Chemistry
2026-09-17
The reference study introduces a stereoselective strategy for functionalizing the α-hydroxy-β-amino acid scaffold of bestatin and applies it to oxytocinase-family M1 aminopeptidases. Its most important outcome is a cell-active, low-nanomolar IRAP inhibitor with more than 120-fold selectivity over homologous enzymes, supported by crystallographic evidence implicating the GAMEN loop in potency and selectivity.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-17
The reference study develops a localized tumor suppressor replacement strategy in which chemically modified p21 mRNA is encapsulated in lipid nanoparticles and administered intravesically. Its preclinical data link bladder-localized expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression while limiting systemic distribution.
-
Reserpine N1867: Practical Lab Workflow
2026-09-16
Reserpine (SKU N1867) is a defined research material for neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research where solvent compatibility and fresh-solution handling affect reproducibility. It is intended for controlled laboratory use only and should not be used for diagnostic, clinical, therapeutic, or veterinary applications.
-
Tofacitinib (CP-690550) in RA Macrophage Assays
2026-09-16
Tofacitinib (CP-690550) enables mechanistic studies of JAK/STAT-driven inflammation, with particular value in GM-CSF-reprogrammed rheumatoid arthritis macrophages. This workflow connects cytokine signaling blockade with macrophage phenotype, mitochondrial stress, and immune cell proliferation assay design.
-
GW 4869: Exosome Workflow for Lupus Nephritis
2026-09-15
Use GW 4869 to test whether neutral sphingomyelinase-dependent extracellular vesicle release drives podocyte–endothelial injury. This practical workflow combines inhibitor titration, vesicle normalization, HMGB1/TRIM27 readouts, and controls that distinguish reduced exosome release from nonspecific cytotoxicity.
-
STING agonist-1: Designing Causal Immune Assays
2026-09-15
STING agonist-1 enables controlled interrogation of innate immune signaling, B-cell activation, and tertiary lymphoid structure biology. This guide translates recent ESCC findings into assay-design decisions that distinguish direct STING effects from paracrine and CD40-dependent mechanisms.
-
Lamotrigine Beyond Blockade: A Translational BBB Strategy
2026-09-14
Lamotrigine research becomes more informative when sodium-channel pharmacology is integrated with blood-brain barrier transport, lysosomal trapping, serotonin signaling, and cardiac safety questions. This thought-leadership guide shows how to use a validated surrogate barrier workflow to move from compound identity and assay reproducibility toward translationally meaningful exposure and mechanism decisions.